Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.14.6099

MiR-34b/c rs4938723 Polymorphism Significantly Decreases the Risk of Digestive Tract Cancer: Meta-analysis  

Ji, Tian-Xing (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University)
Zhi, Cheng (Department of Clinical Pathology, the Second Affiliated Hospital of Guangzhou Medical University)
Guo, Xue-Guang (Department of Clinical Laboratory, the Third Affiliated Hospital of Guangzhou Medical University)
Zhou, Qiang (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University)
Wang, Guo-Qiang (Department of Gastrointestinal Surgery, Lab of Surgery, the Second Affiliated Hospital of Guangzhou Medical University)
Chen, Bo (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University)
Ma, Fei-Fei (Department of VIP Obstetrics, the Second Affiliated Hospital of Guangzhou Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.14, 2015 , pp. 6099-6104 More about this Journal
Abstract
Background: Previous studies investigating the association between miR-34b/c rs4938723 polymorphism and cancer risk showed inconclusive. Here, we performed meta-analysis to investigate the association between miR- 34b/c rs4938723 polymorphism and digestive cancer risk. Materials and Methods: Literature database including PubMed, OVID, Chinese National Knowledge Infrastructure (CNKI) were searched for publications concerning the association between the miR-34b/c rs4938723 polymorphism and digestive cancer risk. Results: A total of 6 studies consisting of 3246 cases and 3568 controls were included in this meta-analysis. The combined analysis suggested the miR-34b/c rs4938723 polymorphism significantly reduced digestive cancer risk under allelic model, homogeneous co-dominant model and recessive model (C vs T: OR=0.88, 95%CI=0.82-0.95, p-value=0.001; CC vs TT: OR =0.67, 95%CI=0.57-0.80, p-value=0.000; CC vs TT/TC: OR=0.68, 95%CI=0.58-0.80, p-value=0.000). Q-test and I2 test revealed no significant heterogeneity in all genotype comparisons. The Begger's funnel plot and Egger's test did not show significant publication bias. Conclusions: The current evidence supports the conclusion that the miR-34b/c rs4938723 polymorphism decreases an individual's susceptibility to digestive cancers.
Keywords
miR-34b/c; polymorphism; digestive cancer; susceptibility;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Corney DC, Flesken-Nikitin A, Godwin AK, et al (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesionindependent growth. Cancer Res, 67, 8433-8.   DOI
2 Corney DC, Hwang CI, Matoso A, et al (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res, 16, 1119-28.   DOI
3 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI
4 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
5 Gao LB, Li LJ, Pan XM, et al (2013). A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem, 394, 415-20.
6 Han Y, Pu R, Han X, et al (2013). Associations of pri-miR- 34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One, 8, 58564.   DOI
7 He L, He X, Lim LP, et al (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-4.   DOI
8 Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, et al (2011). Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer, 104, 1770-8.   DOI
9 Li L, Wu J, Sima X, et al (2013). Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol, 34, 1919-23.   DOI
10 Lujambio A, Calin GA, Villanueva A, et al (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A, 105, 13556-61.   DOI
11 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
12 Normand SL (1999). Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med, 18, 321-59.   DOI
13 Oh J, Kim JW, Lee BE, et al (2014). Polymorphisms of the primiR- 34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep, 31, 995-1002.
14 Pan XM, Sun RF, Li ZH, et al (2015). Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomarkers.
15 Son MS, Jang MJ, Jeon YJ, et al (2013). Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene, 524, 156-60.   DOI
16 Suzuki H, Yamamoto E, Nojima M, et al (2010). Methylationassociated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis, 31, 2066-73.   DOI
17 Suzuki R, Yamamoto E, Nojima M, et al (2014). Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol, 49, 1135-44.   DOI
18 Tao T, Chen S, Xu B, et al (2014). Association between hsamiR- 34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res, 26, 315-22.
19 Tian Q, Jia J, Ling S, et al (2014). A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol, 40, 67-72.   DOI
20 Toyota M, Suzuki H, Sasaki Y, et al (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res, 68, 4123-32.   DOI
21 Vogt M, Munding J, Gruner M, et al (2011). Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch, 458, 313-22.   DOI
22 Wang LQ, Kwong YL, Wong KF, et al (2014). Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J Transl Med, 12, 52.   DOI
23 Wang Z, Wu J, Zhang G, et al (2013). Associations of miR- 499 and miR-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract, 2013, 719202.
24 Xu Y, Liu L, Liu J, et al (2011). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer, 128, 412-7.   DOI
25 Xue W, Zhu M, Wang Y, et al (2015). Association between PLCE1 rs2274223 A > G polymorphism and cancer risk: proof from a meta-analysis. Sci Rep, 5, 7986.   DOI
26 Yang C, Ma X, Liu D, et al (2014). Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. Tumour Biol, 35, 12545-54.   DOI
27 Yi DH, Wang BG, Zhong XP, et al (2014). Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol, 35, 11967-75.   DOI
28 Yin J, Wang X, Zheng L, et al (2013). Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One, 8, 80570.   DOI
29 Zhang J, Huang X, Xiao J, et al (2014a). Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One, 9, 100055.   DOI
30 Zhang S, Qian J, Cao Q, et al (2014b). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis, 29, 149-54.   DOI
31 Chen X, Hu H, Guan X, et al (2012). CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer, 130, 1607-13.   DOI
32 Bensen JT, Tse CK, Nyante SJ, et al (2013). Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the carolina breast cancer study. Cancer Causes Control, 24, 1099-109.   DOI